Nuvectis Pharma, Inc.
NVCT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875558
No open-market purchases or sales by Nuvectis Pharma, Inc. insiders were filed in the last 90 days; 94 institutions reported holding it in 13F filings for Q3 2026, worth $272.1M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:23 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 11, 2026 | Feb 25, 2025 | Mar 5, 2024 | Mar 7, 2023 |
| Research and development | $18.2M | $12.9M | $15.4M | $13.2M |
| Selling, general and administrative | $9.42M | $6.93M | $7.52M | $6.01M |
| Operating income | -$27.6M | -$19.8M | -$22.9M | -$19.2M |
| Net income | -$26.4M | -$19.0M | -$22.3M | -$19.1M |
| EPS, basic | $-1.32 | $-1.11 | $-1.43 | $-1.51 |
| EPS, diluted | $-1.32 | $-1.11 | $-1.43 | $-1.51 |
| Weighted shares, basic | 21.8M | 17.1M | 15.6M | 12.7M |
| Weighted shares, diluted | 21.8M | 17.1M | 15.6M | 12.7M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 11, 2026 | Feb 25, 2025 | Mar 5, 2024 | Mar 7, 2023 |
| Cash and equivalents | $31.6M | $18.5M | $19.1M | $20.0M |
| Total current assets | $31.7M | $18.6M | $19.2M | $20.4M |
| Total assets | $31.7M | $18.6M | $19.2M | $20.4M |
| Accounts payable | $6.27M | $2.50M | $2.77M | $2.91M |
| Total current liabilities | $13.3M | $8.89M | $6.98M | $6.19M |
| Total liabilities | $13.3M | $8.89M | $6.98M | $6.19M |
| Shareholders' equity | $18.4M | $9.71M | $12.2M | $14.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 11, 2026 | Feb 25, 2025 | Mar 5, 2024 | Mar 7, 2023 |
| Operating cash flow | -$16.0M | -$12.2M | -$16.0M | -$13.6M |
| Stock-based compensation | $6.03M | $4.86M | $4.71M | $1.71M |
| Investing cash flow | – | $0 | $0 | – |
| Financing cash flow | $29.1M | $11.7M | $15.1M | $27.8M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 30, 2026 | 34.4M | +34.3% | SEC |
| Jul 31, 2026 | 32.6M | +28.0% | SEC |
| May 1, 2026 | 26.5M | +12.2% | SEC |
| Feb 6, 2026 | 26.5M | +13.3% | SEC |
| Nov 1, 2025 | 25.6M | +32.6% | SEC |
| Aug 1, 2025 | 25.5M | +36.5% | SEC |
| May 1, 2025 | 23.6M | +28.8% | SEC |
| Feb 21, 2025 | 23.4M | +31.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.